Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer

被引:20
|
作者
Jeremic, B
Shibamoto, Y
机构
[1] KYOTO UNIV, CHEST DIS RES INST, DEPT ONCOL, KYOTO 60601, JAPAN
[2] UNIV HOSP, DEPT ONCOL, KRAGUJEVAC, YUGOSLAVIA
关键词
radiotherapy; hyperfractionation; interfraction interval; nonsmall cell lung cancer;
D O I
10.1016/0360-3016(95)02158-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the influence of interfraction interval in hyperfractionated radiotherapy (HFX RT) with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer. Methods and Materials: One hundred sixty-nine patients treated in a randomized study were retrospectively analyzed. Group I patients were treated by HFX RT with 1.2 Gy twice daily with a total dose of 64.8 Gy in 27 treatment days, while Groups II and III patients were treated by the same HFX RT and concurrent chemotherapy with carboplatin and etoposide (every week in Group II and every other week in Group III). Interfraction intervals of either 4.5-5 h or 5.5-6 h were used for each patient. Results: Patients treated with shorter interfraction intervals (4.5-5 h) had a better prognosis than those treated with longer intervals (5.5-6 h)(median survival: 22 vs. 7 months; 5-year survival rate: 27% vs. 0%, p = 0.00000). This phenomenon was observed in all treatment groups. Patients greater than or equal to 60 years of age, with Stage IIIA disease, or with previous weight loss less than or equal to 5% were treated more often with the shorter intervals than those < 60 years, with Stage IIIB disease, or with weight loss > 5%, respectively, but in all of these subgroups of patients, the shorter intervals were associated with a better prognosis. Multivariate analysis showed that the interfraction interval was an independent prognostic factor, together with sex, age, performance status, and stage, The shorter intervals were associated with an increased incidence of acute high grade toxicity, but not with an increase in late toxicity. Conclusion: Patients treated with shorter interfraction intervals (4.5-5 h) appeared to have a better survival than those treated with longer intervals (5.5-6 h). Prospective randomized studies are warranted to further investigate the influence of interfraction interval in HFX RT.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 50 条
  • [41] Safety and Efficacy of Hypofractionated Radiotherapy and Concurrent Chemotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer
    Zhang, Q.
    Fu, X. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E124 - E124
  • [42] CONCURRENT CHEMOTHERAPY (CT) AND RADIOTHERAPY (RT) IN LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER (NSCLC) - A REVIEW
    MIRIMANOFF, RO
    LUNG CANCER, 1994, 11 : S79 - S99
  • [43] PRETREATMENT PROGNOSTIC FACTORS IN PATIENTS WITH STAGE-III NON-SMALL-CELL LUNG-CANCER TREATED WITH HYPERFRACTIONATED RADIATION-THERAPY WITH OR WITHOUT CONCURRENT CHEMOTHERAPY
    JEREMIC, B
    SHIBAMOTO, Y
    LUNG CANCER, 1995, 13 (01) : 21 - 30
  • [44] International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?
    Putora, Paul Martin
    Leskow, Pawel
    McDonald, Fiona
    Batchelor, Tim
    Evison, Matthiew
    ERJ OPEN RESEARCH, 2020, 6 (01)
  • [45] Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer
    Wada, Kentaro
    Kishi, Noriko
    Kanayama, Naoyuki
    Hirata, Takero
    Morimoto, Masahiro
    Konishi, Koji
    Imamura, Fumio
    Teshima, Teruki
    Ogawa, Kazuhiko
    ANTICANCER RESEARCH, 2018, 38 (10) : 5951 - 5958
  • [46] Uptake of Adjuvant Durvalumab After Definitive Concurrent Chemoradiotherapy for Stage III Nonsmall-cell Lung Cancer
    Bryant, Alex K.
    Yin, Huiying
    Schipper, Matthew J.
    Paximadis, Peter A.
    Boike, Thomas P.
    Bergsma, Derek P.
    Movsas, Benjamin
    Dess, Robert T.
    Mietzel, Melissa A.
    Kendrick, Randi
    Seferi, Merita
    Dominello, Michael M.
    Matuszak, Martha M.
    Jagsi, Reshma
    Hayman, James A.
    Pierce, Lori J.
    Jolly, Shruti
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (04): : 142 - 145
  • [47] Moderate dose hyperfractionated radiotherapy and concurrent chemotherapy for head and neck cancer
    Aref, A.
    Chuba, P.
    Samani, K.
    Toole, A.
    Leonard, R.
    Salama, D.
    Denton, L.
    Patel, D.
    Agnone, E.
    Browne, C.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S344 - S345
  • [48] Interdisciplinary multimodality management of stage III nonsmall cell lung cancer
    Huber, Rudolf M.
    De Ruysscher, Dirk
    Hoffmann, Hans
    Reu, Simone
    Tufman, Amanda
    EUROPEAN RESPIRATORY REVIEW, 2019, 28 (152):
  • [49] Recurrence patterns with concurrent platinum-based chemotherapy and accelerated hyperfractionated radiotherapy in stage III and IV head and neck cancer patients
    Koness, RJ
    Glicksman, A
    Liu, L
    Coachman, N
    Landman, C
    Slotman, G
    Wanebo, HJ
    AMERICAN JOURNAL OF SURGERY, 1997, 174 (05): : 532 - 535
  • [50] Continuous hyperfractionated accelerated radiotherapy using modern radiotherapy techniques for nonsmall cell lung cancer patients unsuitable for chemoradiation
    Shrimali, R. K.
    Arunsingh, M.
    Das, A.
    Mallick, I
    Mahata, A.
    Prasath, S.
    Achari, R.
    Chatterjee, S.
    INDIAN JOURNAL OF CANCER, 2017, 54 (01) : 120 - 126